Th17 cell inhibitor / Merck (MSD), Lycera - LARVOL DELTA

scRNA-seq of the immune microenvironment reveals immunotherapy response biomarkers in high-risk SMM (YouTube) - "Irene Ghobrial, MD...comments on a study that used single-cell RNA-sequencing (scRNA-seq) on CD138-immune cells from patients with high-risk SMM to investigate potential immune biomarkers. Samples were taken at baseline, at the start of cycle 9, and at the end of treatment from patients enrolled in a Phase II trial of elotuzumab, lenalidomide, and dexamethasone. It was shown that a higher abundance of mature B-cells, Th17 cells, and GZMK cells was associated with significantly longer progression-free survival (PFS) in SMM patients. These differences reflect how normal-like a patient's immune composition is at baseline."

Interview • Video